Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography

Zhu,Juming; Peng,Qing; Su,Tu; Wang,Minli; Wang,Fang

doi:10.3892/etm.2020.9491

Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography

Authors:
- Juming Zhu
- Qing Peng
- Tu Su
- Minli Wang
- Fang Wang
View Affiliations

Affiliations: Department of Ophthalmology, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Ophthalmology, Tenth People's Hospital, Shanghai 200072, P.R. China
Published online on: November 19, 2020 https://doi.org/10.3892/etm.2020.9491
Article Number: 59

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the efficacy of three consecutive anti‑VEGF treatments in patients with neovascular macular degeneration (nAMD) was assessed by optical coherence tomography angiography (OCT‑A). A total of 23 eyes with nAMD were treated with intravitreal injections (IVIs) of ranibizumab once a month for three consecutive months. There were eight follow‑up time‑points: Prior to the initial IVI and on days 1, 3, 7, 14, 30, 60 and 90 after the first IVI. The follow‑up examinations consisted of measurements of the best‑corrected visual acuity (BCVA), the height of retinal pigmented epithelium detachment (RPED), the greatest linear dimension (GLD), choroidal neovascularization (CNV) flow area, whole retinal thickness and four‑quadrant retinal thickness. The results indicated that, when compared with the baseline, the BCVA gradually improved after IVI and improved significantly on days 60 and 90 (P<0.05); the RPED and GLD improved after IVI, with a significant improvement on days 30, 60 and 90 (all, P<0.05); the CNV flow area was gradually shortened in the early stage after IVI but rebounded on day 30, while the difference was statistically significant on day 14 (P<0.05). The temporal retinal thickness was statistically significant on day 30 (P<0.05) and there were statistically significant differences in nasal and inferior retinal thickness on days 14 and 30 compared with prior to IVI (all, P<0.05). The BCVA was positively correlated with the RPED, GLD, CNV flow area and nasal retinal thickness (all, P<0.05). In conclusion, OCT‑A may provide an effective reference to guide the evaluation, treatment and monitoring of nAMD. The present study was registered in the Chinese Clinical Trial Registry (CChiTR; no. ChiCTR1900023607; http://www.chictr.org.cn/listbycreater.aspx).

View Figures

View References

1	Ambati J, Ambati BK, Yoo SH, Ianchulev S and Adamis AP: Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 48:257–293. 2003.PubMed/NCBI View Article : Google Scholar
2	Anderson DH, Mullins RF, Hageman GS and Johnson LV: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 134:411–431. 2002.PubMed/NCBI View Article : Google Scholar
3	Jager RD, Mieler WF and Miller JW: Age-related macular degeneration. N Engl J Med. 358:2606–2617. 2008.PubMed/NCBI View Article : Google Scholar
4	Ardeljan C, Ardeljan D, Abu-Asab M and Chan CC: Inflammation and cell death in age-related macular degeneration: An immunopathological and ultrastructural model. J Clin Med. 3:1542–1560. 2014.PubMed/NCBI View Article : Google Scholar
5	Cho Y, Cao X, Shen D, Tuo J, Parver LM, Rickles FR and Chan CC: Evidence for enhanced tissue factor expression in age-related macular degeneration. Lab Investig. 91:519–526. 2011.PubMed/NCBI View Article : Google Scholar
6	MacHalińska A, Kłos P, Safranow K, Dziedziejko V, Rudnicki M, Paczkowska E, Karczewicz D and Machaliński B: Neural stem/progenitor cells circulating in peripheral blood of patients with neovascular form of AMD: A novel view on pathophysiology. Graefes Arch Clin Exp Ophthalmol. 249:1785–1794. 2011.PubMed/NCBI View Article : Google Scholar
7	Faridi A, Jia Y, Gao SS, Huang D and Bhavsar KV: Sensitivity and Speci fi city of OCT angiography to detect choroidal neovascularization. Ophthalmol Retin. 1:294–303. 2017.PubMed/NCBI View Article : Google Scholar
8	Schneider EW and Fowler SC: Optical coherence tomography angiography in the management of age-related macular degeneration. Curr Opin Ophthalmol. 29:217–225. 2018.PubMed/NCBI View Article : Google Scholar
9	Lupidi M, Cerquaglia A, Chhablani J, Fiore T, Singh SR, Cardillo Piccolino F, Corbucci R, Coscas F, Coscas G and Cagini C: Optical coherence tomography angiography in age-related macular degeneration: The game changer. Eur J Ophthalmol. 28:349–357. 2018.PubMed/NCBI View Article : Google Scholar
10	Kaszubski PA, Ben Ami T, Saade C, Nabati C, Kumar V, Santos AR, Silva R, Cachulo ML, Cunha-Vaz JG and Smith RT: Changes in reticular pseudodrusen area in eyes that progressed from early to late age-related macular degeneration. Int Ophthalmol. 38:503–511. 2018.PubMed/NCBI View Article : Google Scholar
11	Aggarwal K, Agarwal A, Sharma A, Sharma K and Gupta V: OCTA Study Group. Detection of type 1 choroidal neovascular membranes using optical coherence tomography angiography in tubercular posterior uveitis. Retina. 39:1595–1606. 2018.
12	Nesper PL, Soetikno BT, Treister AD and Fawzi AA: Volume-rendered projection-resolved OCT angiography: 3D lesion complexity is associated with therapy response in wet age-related macular degeneration. Investig Ophthalmol Vis Sci. 59:1944–1952. 2018.PubMed/NCBI View Article : Google Scholar
13	Pilotto E, Frizziero L, Daniele AR, Convento E, Longhin E, Guidolin F, Parrozzani R, Cavarzeran F and Midena E: Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF. Br J Ophthalmol. 103:67–71. 2019.PubMed/NCBI View Article : Google Scholar
14	Fauser S, Schwabecker V and Muether PS: Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 158:532–536. 2014.PubMed/NCBI View Article : Google Scholar
15	Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 119:2537–2548. 2012.PubMed/NCBI View Article : Google Scholar
16	Liu F, Ding X, Yang Y, Li J, Tang M, Yuan M, Hu A, Zhan Z, Li Z and Lu L: Aqueous humor cytokine profiling in patients with wet AMD. Mol Vis. 22:352–361. 2016.PubMed/NCBI
17	Nowak JZ: Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol Rep. 58:353–363. 2006.PubMed/NCBI
18	Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach KG, Lu L, Ufret RL, Salomon RG and Perez VL: Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 14:194–198. 2008.PubMed/NCBI View Article : Google Scholar
19	Chen M and Xu H: Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 98:713–725. 2015.PubMed/NCBI View Article : Google Scholar
20	Xu H, Chen M and Forrester JV: Para-inflammation in the aging retina. Prog Retin Eye Res. 28:348–368. 2009.PubMed/NCBI View Article : Google Scholar
21	CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL and Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 364:1897–1908. 2011.PubMed/NCBI View Article : Google Scholar
22	Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Writing Committee. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M and Ferris FL III. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 127 (Suppl):S135–S145. 2020.PubMed/NCBI View Article : Google Scholar
23	Shah ND and Barkmeier AJ: Risk of systemic adverse events following intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology: Aug 8, 2020 2020 (Epub ahead of print).
24	Sun X, Xu X and Zhang X: Counterfeit bevacizumab and endophthalmitis. N Engl J Med. 365:378–379. 2011.PubMed/NCBI View Article : Google Scholar
25	Wang F, Yu S, Liu K, Chen FE, Song Z, Zhang X, Xu X and Sun X: Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai China. Ophthalmology. 120:355–361. 2013.PubMed/NCBI View Article : Google Scholar
26	Huang HB, Pan Y and Liu T: Shanghai eye treatment outbreak: Bevacizumab therapy for AMD in China. Clin Exp Optom. 96:106–108. 2013.PubMed/NCBI View Article : Google Scholar